New scan could replace biopsies for breast cancer treatment decisions
NCT ID NCT05742269
First seen Mar 15, 2026 · Last updated Apr 24, 2026 · Updated 5 times
Summary
This study aimed to see if a special PET/CT scan could better identify which patients with metastatic triple-negative breast cancer would benefit from immunotherapy. The scan looks for a protein called PD-L1 throughout the whole body, unlike standard biopsies that only test one spot. Only 3 people enrolled before the study ended, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Karolinska University Hospital
Stockholm, 171 76, Sweden
Conditions
Explore the condition pages connected to this study.